Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$53.84
-3.3%
$71.75
$37.55
$91.10
$4.57B1.761.80 million shs799,595 shs
Integer Holdings Co. stock logo
ITGR
Integer
$113.01
-8.3%
$112.68
$69.40
$123.99
$3.79B1.1327,879 shs786,282 shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$13.80
-1.6%
$15.06
$11.03
$21.22
$1.76B1.1887,864 shs258,334 shs
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
$13.67
+1.3%
$13.47
$11.22
$16.35
$2.41B-0.073,963 shs3,666 shs
Nevro Corp. stock logo
NVRO
Nevro
$11.71
-6.4%
$14.16
$11.49
$34.86
$429.52M0.89472,232 shs150,710 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-1.35%+0.16%-21.71%-11.48%+12.58%
Integer Holdings Co. stock logo
ITGR
Integer
+4.60%+4.09%+7.88%+21.72%+52.78%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-0.92%+2.56%-4.95%-11.76%-2.16%
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
+1.37%+4.71%+5.99%-10.85%-2.67%
Nevro Corp. stock logo
NVRO
Nevro
-2.19%+1.95%-8.21%-30.66%-61.71%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.7861 of 5 stars
4.22.00.00.01.82.50.6
Integer Holdings Co. stock logo
ITGR
Integer
1.4253 of 5 stars
1.32.00.00.02.31.73.1
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
1.8728 of 5 stars
3.41.00.00.02.42.50.6
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
N/AN/AN/AN/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
1.6749 of 5 stars
4.02.00.00.00.01.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.38
Hold$76.2941.69% Upside
Integer Holdings Co. stock logo
ITGR
Integer
2.67
Moderate Buy$120.506.63% Upside
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.80
Moderate Buy$19.5041.30% Upside
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
N/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$21.2381.30% Upside

Current Analyst Ratings

Latest NEO, NVRO, NHNKY, CRSP, and ITGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$88.00 ➝ $89.00
4/15/2024
Integer Holdings Co. stock logo
ITGR
Integer
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$105.00 ➝ $135.00
4/15/2024
Nevro Corp. stock logo
NVRO
Nevro
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/11/2024
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
4/11/2024
Nevro Corp. stock logo
NVRO
Nevro
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/9/2024
Integer Holdings Co. stock logo
ITGR
Integer
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$123.00 ➝ $139.00
4/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00
3/28/2024
Integer Holdings Co. stock logo
ITGR
Integer
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$105.00 ➝ $130.00
3/14/2024
Integer Holdings Co. stock logo
ITGR
Integer
CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$137.00
3/6/2024
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$82.00 ➝ $99.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$371.21M12.31N/AN/A$23.70 per share2.27
Integer Holdings Co. stock logo
ITGR
Integer
$1.60B2.37$7.61 per share14.85$45.58 per share2.48
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$591.64M2.98$0.28 per share50.16$7.39 per share1.87
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
$1.53B1.58$0.86 per share15.82$7.03 per share1.94
Nevro Corp. stock logo
NVRO
Nevro
$425.17M1.01N/AN/A$8.10 per share1.45

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$153.61M-$1.96N/AN/AN/AN/A-8.09%-6.73%5/13/2024 (Estimated)
Integer Holdings Co. stock logo
ITGR
Integer
$90.65M$2.6942.0118.411.635.68%10.80%5.48%4/25/2024 (Confirmed)
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$87.97M-$0.70N/AN/AN/A-14.87%-4.13%-2.33%4/30/2024 (Confirmed)
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
$126.61M$0.7019.52N/A7.60%9.39%7.37%N/A
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%5/7/2024 (Confirmed)

Latest NEO, NVRO, NHNKY, CRSP, and ITGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nevro Corp. stock logo
NVRO
Nevro
-$1.02N/A+$1.02N/AN/AN/A  
4/30/2024N/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$0.0270N/A+$0.0270N/AN/AN/A  
4/25/2024N/A
Integer Holdings Co. stock logo
ITGR
Integer
$1.12$1.14+$0.02N/A$412.78 million$414.80 million  
2/21/2024Q4 2023
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$0.15$1.10+$0.95$1.10$148.72 million$201.20 million
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million
2/20/2024Q4 2023
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$0.07-$0.02+$0.05$0.07$152.90 million$155.55 million
2/15/2024Q4 2023
Integer Holdings Co. stock logo
ITGR
Integer
$1.34$1.39+$0.05$2.00$409.04 million$413.15 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
N/AN/AN/AN/AN/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
N/AN/AN/AN/AN/A
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
$0.141.02%N/A20.00%N/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
17.54
17.54
Integer Holdings Co. stock logo
ITGR
Integer
0.64
2.80
1.71
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
0.57
6.20
5.95
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
N/A
4.03
2.53
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Integer Holdings Co. stock logo
ITGR
Integer
99.29%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
98.50%
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
0.10%
Nevro Corp. stock logo
NVRO
Nevro
95.52%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.10%
Integer Holdings Co. stock logo
ITGR
Integer
2.00%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
1.30%
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
N/A
Nevro Corp. stock logo
NVRO
Nevro
3.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
47384.88 million81.40 millionOptionable
Integer Holdings Co. stock logo
ITGR
Integer
10,50033.50 million32.83 millionOptionable
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2,100127.67 million126.01 millionOptionable
Nihon Kohden Co. stock logo
NHNKY
Nihon Kohden
5,751176.46 millionN/ANot Optionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.51 millionOptionable

NEO, NVRO, NHNKY, CRSP, and ITGR Headlines

SourceHeadline
Federated Hermes Inc. Has $9.28 Million Position in Nevro Corp. (NYSE:NVRO)Federated Hermes Inc. Has $9.28 Million Position in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 25 at 5:33 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
finance.yahoo.com - April 17 at 10:38 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
prnewswire.com - April 17 at 8:30 AM
Nevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of CanadaNevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:44 AM
Nevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of CanadaNevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of Canada
marketbeat.com - April 15 at 3:31 PM
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 12 at 2:33 AM
Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00
marketbeat.com - April 11 at 8:25 AM
Nevro (NYSE:NVRO) Trading Up 5.5%Nevro (NYSE:NVRO) Trading Up 5.5%
marketbeat.com - April 9 at 12:12 PM
Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 5 at 4:35 AM
Where Nevro Stands With AnalystsWhere Nevro Stands With Analysts
benzinga.com - April 3 at 1:52 PM
Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00
marketbeat.com - April 3 at 12:14 PM
Nevro (NYSE:NVRO) Stock Price Down 4.8%Nevro (NYSE:NVRO) Stock Price Down 4.8%
marketbeat.com - April 1 at 2:58 PM
EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization
finanznachrichten.de - March 25 at 4:30 PM
Heres Why You Should Retain Nevro (NVRO) Stock for NowHere's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com - March 21 at 1:36 PM
NVRO Mar 2024 20.000 putNVRO Mar 2024 20.000 put
finance.yahoo.com - March 11 at 12:27 AM
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral ScrewNevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
zacks.com - February 29 at 8:31 AM
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
prnewswire.com - February 28 at 4:10 PM
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
markets.businessinsider.com - February 27 at 1:07 AM
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
markets.businessinsider.com - February 26 at 7:38 AM
Nevro just downgraded at Oppenheimer, heres whyNevro just downgraded at Oppenheimer, here's why
realmoney.thestreet.com - February 23 at 2:42 AM
Nevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - February 22 at 9:41 PM
Why Nevro Stock Lagged the Market on ThursdayWhy Nevro Stock Lagged the Market on Thursday
fool.com - February 22 at 6:21 PM
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 OutlookHold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
markets.businessinsider.com - February 22 at 2:16 PM
Analyst Scoreboard: 4 Ratings For NevroAnalyst Scoreboard: 4 Ratings For Nevro
markets.businessinsider.com - February 22 at 2:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CRISPR Therapeutics logo

CRISPR Therapeutics

NASDAQ:CRSP
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Integer logo

Integer

NYSE:ITGR
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
NeoGenomics logo

NeoGenomics

NASDAQ:NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Nihon Kohden logo

Nihon Kohden

OTCMKTS:NHNKY
Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.